Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Merck
Express Scripts
Baxter
Medtronic

Last Updated: March 22, 2023

Details for New Drug Application (NDA): 206255


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


NDA 206255 describes SOOLANTRA, which is a drug marketed by Galderma Labs Lp and is included in one NDA. It is available from two suppliers. There are twelve patents protecting this drug and one Paragraph IV challenge. Additional details are available on the SOOLANTRA profile page.

The generic ingredient in SOOLANTRA is ivermectin. There are five drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the ivermectin profile page.
Summary for 206255
Tradename:SOOLANTRA
Applicant:Galderma Labs Lp
Ingredient:ivermectin
Patents:12
Formulation / Manufacturing:see details
Pharmacology for NDA: 206255
Medical Subject Heading (MeSH) Categories for 206255
Suppliers and Packaging for NDA: 206255
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SOOLANTRA ivermectin CREAM;TOPICAL 206255 NDA Galderma Laboratories, L.P. 0299-3823 0299-3823-00 2 g in 1 TUBE (0299-3823-00)
SOOLANTRA ivermectin CREAM;TOPICAL 206255 NDA Galderma Laboratories, L.P. 0299-3823 0299-3823-02 1 TUBE in 1 BLISTER PACK (0299-3823-02) / 2 g in 1 TUBE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CREAM;TOPICALStrength1%
Approval Date:Dec 19, 2014TE:ABRLD:Yes
Patent:See Plans and PricingPatent Expiration:Mar 13, 2034Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
Patent:See Plans and PricingPatent Expiration:Apr 22, 2024Product Flag?YSubstance Flag?Delist Request?
Patent:See Plans and PricingPatent Expiration:Apr 22, 2024Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.

Expired US Patents for NDA 206255

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Galderma Labs Lp SOOLANTRA ivermectin CREAM;TOPICAL 206255-001 Dec 19, 2014 See Plans and Pricing See Plans and Pricing
Galderma Labs Lp SOOLANTRA ivermectin CREAM;TOPICAL 206255-001 Dec 19, 2014 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Medtronic
Moodys
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.